MBIO: חוב להון עצמי Mustang Bio Inc

Mustang Bio, Inc. (MBIO) focuses on developing advanced CAR-T therapies to combat oncology and hereditary pathologies. However, global instability and sanctions hinder the conduct of cross-border trials and disrupt the supply of biologics. The debt-to-equity ratio stands at 0.00, while the company relies heavily on third-party logistics and vector suppliers, as reflected in the daily price action on the GURU.Markets chart.

The total leverage ratio determines the proportion of borrowed funds within the financing structure, allowing investors to assess the financial stability and default risk of an enterprise. The trend in the ratio of total liabilities to equity demonstrates the ability of Mustang Bio, Inc. (MBIO) to sustain the development of costly gene therapies and CAR-T products without excessive debt pressure prior to product commercialization.